John Forster Robbins

US Patent:

8383133, Feb 26, 2013

Filed:

Oct 15, 2007

Appl. No.:

12/444963

Inventors:

Rachel Schneerson - Bethesda MD, US
Yimin Wu - Frederick MD, US
Louis Miller - Cabin John MD, US
Fathy D. Majadly - Frederick MD, US
John B. Robbins - New York NY, US

Assignee:

The United States of America, as Represented by the Secretary, Department of Health and Human Services - Washington DC

International Classification:

A61K 39/015
C07K 14/445

US Classification:

4242721, 4242681, 530350

Abstract:

Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against , the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.

US Patent:

8394387, Mar 12, 2013

Filed:

Jul 31, 2007

Appl. No.:

11/831860

Inventors:

Stephen H. Leppla - Bethesda MD, US
Mary Jo Rosovitz - Germantown MD, US
John B. Robbins - New York NY, US
Rachel Schneerson - Bethesda MD, US
S. Dana Hsu - Bethesda MD, US
Joseph Shiloach - Rockville MD, US
Delia M. Ramirez - Bethesda MD, US

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/07
A61K 39/02
A61K 39/00
A61K 38/00

US Classification:

4242461, 4242341, 4241851, 4241901, 4241841, 530300, 530324, 530350

Abstract:

The invention relates to improved methods of producing and recovering sporulation-deficient mutant stains, and for producing and recovering recombinant protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, bacterial infections and which are useful to prevent and/or treat illnesses caused by , such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.

US Patent:

8444996, May 21, 2013

Filed:

Oct 1, 2009

Appl. No.:

13/121574

Inventors:

Rachel Schneerson - Bethesda MD, US
John B. Robbins - New York NY, US
Fathy Majadly - Frederick MD, US
Christopher P. Mocca - Columbia MD, US
Jerry Keith - Olney NC, US
Louis Miller - Cabin John MD, US
Ruth Nussenzweig - New York NY, US
Darrell T. Liu - Bethesda MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC
New York University - New York NY

International Classification:

A61K 39/015
A61K 39/385

US Classification:

4241931, 4241941, 4242651, 4242721

Abstract:

Disclosed are immunogenic conjugates which elicit an immune response to proteins. In particular examples, the proteins include sexual stage surface proteins, circumsporozoite protein (CSP), or immunogenic portions of CSP. Also provided herein are immunogenic compositions including one or more of the disclosed immunogenic conjugates and a pharmaceutically acceptable carrier. Further provided is a method of eliciting an immune response to in a subject, comprising administering to the subject an immunogenic composition disclosed herein.

US Patent:

20100150954, Jun 17, 2010

Filed:

Aug 14, 2009

Appl. No.:

12/541804

Inventors:

Mark A. Miller - Chevy Chase MD, US
Rachel Schneerson - Bethesda MD, US
John B. Robbins - New York NY, US
Jerry Keith - Olney MD, US

International Classification:

A61K 39/385
A61P 31/16
C07K 17/06

US Classification:

4241941, 530404

Abstract:

Disclosed are immunogenic conjugates having the general formula:were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid residue present in the M2e peptide; S the sulfur present in the cysteine amino acid residue; CH2-CO—NH—CH2-CH2-CO the linking group; NH the amine group present in a lysine residue of the carrier; Lys is a lysine amino acid residue and Pr the carrier protein. Also disclosed are isolated immunogens that include an immunogenic fragment of an influenza HA protein including the polybasic cleavage site, wherein the immunogenic fragment of the influenza HA protein has been modified to remove an N-terminal leader amino acid sequence and a C-terminal transmembrane domain. Also disclosed are methods producing an influenza vaccine specific for an identified influenza strain.

US Patent:

20100330074, Dec 30, 2010

Filed:

Feb 17, 2009

Appl. No.:

12/918281

Inventors:

Evguenii Vinogradov - Gatineau, CA
Rachel Schneerson - Bethesda MD, US
Haijing Hu - Montgomery Village MD, US
Stephen H. Leppla - Bethesda MD, US
John B. Robbins - New York NY, US

International Classification:

A61K 39/395
A61K 39/07
G01N 33/569
C07K 16/12
C07K 14/00
C07H 1/00

US Classification:

4241301, 4242461, 435 732, 5303871, 5303884, 530395, 5361231

Abstract:

Provided are immunogenic compositions and methods for eliciting an immune response against and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutyrate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutyrate-substituted saccharides elicit an effective immune response against spores in mammalian hosts to which the conjugates are administered.

US Patent:

20110212125, Sep 1, 2011

Filed:

Aug 14, 2009

Appl. No.:

13/059051

Inventors:

John B. Robbins - New York NY, US
Rachel Schneerson - Bethesda MD, US
Christopher P. Mocca - Columbia MD, US
Evguenii Vinogradov - Ottawa, CA

International Classification:

A61K 39/385
C07K 14/765
C07K 14/34
A61P 31/04
A61P 37/04

US Classification:

42419711, 530363, 530350

Abstract:

Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an infection. The disclosed immunogenic conjugates have the general structure:wherein Pr is a carrier protein, Sr is an optional spacer moiety, Kdo is an 3-deoxy-D-manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from In specific examples, the immunogenic conjugates include the core oligosaccharide obtained from having the structure:In specific examples, the disaccharide repeat unit included in the immunogenic conjugate has the structure:

US Patent:

20120009219, Jan 12, 2012

Filed:

Sep 23, 2011

Appl. No.:

13/244060

Inventors:

Stephen H. Leppla - Bethesda MD, US
Yogendra Singh - Delhi, IN
Kurt Klimpel - San Diego CA, US
Rachel Schneerson - Bethesda MD, US
John B. Robbins - New York NY, US

International Classification:

A61K 39/07
A61P 31/04
A61P 37/04
C07K 14/32
C12N 1/21

US Classification:

4242461, 530350, 4352525

Abstract:

The invention relates to improved methods of producing and recovering protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, bacterial infections and which are useful to prevent and/or treat illnesses caused by , such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.

US Patent:

20130129777, May 23, 2013

Filed:

Jan 25, 2013

Appl. No.:

13/750495

Inventors:

The United States of America as represented by the Secretary, Department of Health and Human Services - Bethesda MD, US
Yimin Wu - Frederick MD, US
Louis Miller - Cabin John MD, US
Fathy Majadly - Frederick MD, US
John B. Robbins - New York City NY, US

Assignee:

The United States of America as represented by the Secretary, Department of Health and Human Service - Bethesda MD

International Classification:

C07K 14/705
C07K 14/21

US Classification:

42419711, 530405, 4241931, 530404

Abstract:

Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against , the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.